Log In
Wednesday 21st August 2019

Keryx Biopharmaceuticals

Keryx Biopharmaceuticals, Inc.
750 Lexington Ave. - 20th Floor
New York, NY 10022

Tel: 1-212-531-5965
Fax: 1-212-531-5961
www: http://www.keryx.com/page.cfm?hmid=&smid=&pg=main
Sub-category: Company - Medical Equipment


Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx's lead compound under development is SulonexTM (sulodexide oral gelcap), previously referred to as KRX-101, a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes.

Sulonex is in a pivotal Phase III and Phase IV clinical program under a Special Protocol Assessment (SPA) with the Food & Drug Administration. Additionally, Keryx is developing ZerenexTM, an oral, inorganic, iron-based compound that has the capacity to bind to phosphorous and form non-absorbable complexes.

Zerenex is currently in Phase II clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease (ESRD). Keryx is also developing clinical-stage oncology compounds, including KRX-0401, a novel, first-in-class, oral modulator of Akt, a pathway associated with tumor survival and growth, and other important signal transduction pathways.

KRX-0401 is currently in Phase II clinical development for multiple tumor types. Keryx also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates.

Back to list of organisations

M3 - For secure managed hosting over N3 or internet
© Mayden Foundation 2019